Flash Buy: Pick up Shares of This Breakthrough Cancer Company

Many of you approached Patrick in Vancouver and emailed us asking what supplements Patrick was taking and what you should be taking… Today, Patrick is meeting with ChromaDex Corp. (OTCBB: CDXC) CEO Frank Jaksch to talk about just that. As you may remember from last week, Jaksch sits at the pinnacle of an information network that includes most of the top phytochemical researchers. There is no one better informed about supplements that actually work.

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access.
Not yet a subscriber? Checkout our publication below and get access today!

Breakthrough Technology Alert

This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now… Breakthrough Technology Alert tirelessly researches these exciting new breakthrough technologies to keep you well informed, outline specific opportunities, and keep you ahead of the game.

Patrick Cox has lived deep inside transformative technologies for over 25 years. In the 1980s, he worked in software development and manufacturing. By the mid-‘90s, he consulted for Netscape–which handled 90% of all Internet browsing traffic at the time. InfoWorld and USA Today have featured his research, and he’s written for The Wall Street Journal,...

Related Posts

This is a big deal. Galectin Therapeutics practically owns the entire science of carbohydrate-based therapies. Already, we know that their compounds can inhibit the galectin proteins produced by cancers that kill T-cells. Of even more interest to me is the ability of the same compounds to reverse fibrosis in livers, kidneys and other organs. There is currently no other technology that addresses technology, and this company's technology seems to nail it.

This is huge, folks. In a rational world, the FDA would simply approve FluCide, the leading anti-influenza drug by NanoViricides, Inc. ( OTCBB: NNVC) right now and rush it to market. Further results of a third-party validation were made public Monday morning. They are stunning. Because they are written in “science speak,” it may not be immediately obvious. Previously, I've reported that new tests of NanoViricides' tweaked nanotech FluCide therapy had vastly increased the survival rate of mice given lethal infections of influenza. Roche's Tamiflu, the market leader, increased life spans to an average of 7.8 days. NanoViricides' FluCide increased it to 18.1 days.

The good news is that world-changing scientific breakthroughs are happening right now. Eventually, these breakthroughs will finance incredible growth and recovery. In the meantime, they're going to make individual investors with vision very wealthy.

The folks who answer the customer line at Agora Financial report a number of calls recently asking for an update on our nutraceutical company. I have been looking into there product for several months and following the scandal involving Virginia’s former Republican Gov. Bob McDonnell and his wife, Maureen, who on Friday pleaded not guilty to federal corruption charges related to $145,000 in gifts from CEO…

A number of readers have asked about the announcement by BioTime Inc. (AMEX: BTX) regarding the issuance of warrants. I spoke, as a result, with BioTime's chairman Alfred Kingsley. He explained how these warrants function, as well as their purpose. To raise money for future activities, while avoiding the dilution of current stockholders' equity, BioTime has decided to give existing stockholders warrants. These warrants bestow the right to buy shares of the company's stock for $12.00 at any time in the next four years. One warrant will be issued for every eight shares of BioTime stock.